Drug Repositioning Market

Drug repurposing (also called drug repositioning, reprofiling or re-tasking) is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. This strategy offers various advantages over developing an entirely new drug for a given indication.
Drug Repositioning Market aims to provide a comprehensive presentation of the global market for Drug Repositioning, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Repositioning. Drug Repositioning Market contains market size and forecasts of Drug Repositioning in global, including the following market information:
Global Drug Repositioning Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Drug Repositioning market was valued at US$ 27030 million in 2022 and is projected to reach US$ 36780 million by 2029, at a CAGR of 4.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Drug Repositioning key players include Teva, Novartis, Mylan, Johnson & Johnson, Pfizer, etc. Global top five manufacturers hold a share about 15%.
North America is the largest market, with a share about 40%, followed by Europe and China, both have a share over 30 percent.
In terms of product, Generic Drugs is the largest segment, with a share about 65%. And in terms of application, the largest application is Cancer, followed by Cardiovascular Diseases.
We surveyed the Drug Repositioning companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drug Repositioning Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Drug Repositioning Market Segment Percentages, by Type, 2022 (%)
Generic Drugs
Clinical Trial Failed Drugs
Global Drug Repositioning Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Drug Repositioning Market Segment Percentages, by Application, 2022 (%)
Cardiovascular Diseases
Mental Illness
Cancer
Others
Global Drug Repositioning Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Drug Repositioning Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drug Repositioning revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Drug Repositioning revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Teva
Novartis
Mylan
Johnson & Johnson
Pfizer
Bausch Health
GSK
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drug Repositioning, market overview.
Chapter 2: Global Drug Repositioning market size in revenue.
Chapter 3: Detailed analysis of Drug Repositioning company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drug Repositioning in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.